Korea Stocks, page 7 of 36 — 24 articles published 2026-09-07 ~ 2026-09-09.
Samsung FN REIT (KRX: 448730) 2026 outlook for foreign investors. We cover the Daechi Tower and S-One Building office portfolio, the Samsung Life and Samsung SRA sponsor structure, rate sensitivity, vacancy risk, dilution from follow-on offerings, PFIC tax exposure for US holders, and the dividend yield, LTV, and NAV metrics that matter most.
DSR Steel Corp (KOSPI 069730) stock outlook 2026: a qualitative deep dive into the wire rope and PC steel wire maker supplying cranes, elevators, bridges, and offshore platforms, its wire rod input cost cycle, export ties through affiliate DSR, and offshore wind mooring rope upside.
Chosun Refractories (KRX: 000480) stock outlook 2026 covering its dominant refractory supply position to POSCO and Hyundai Steel, net-cash balance sheet, dividend reliability, crude steel cyclicality, and Korea's governance and value-up debate.
Taekyung Chemical (KRX:006890, formerly Taekyung Chemical Co.) 2026 outlook for global investors: Korea's largest liquefied CO2 and dry ice producer, byproduct-gas feedstock economics, semiconductor and shipbuilding demand exposure, KRX access mechanics, and dividend profile.
Dreamus Company (KRX: 060570) stock outlook 2026 covering the FLO music streaming app's weak position behind Melon and Genie, the iriver and Astell&Kern audio hardware business, SK Square governance risk, and artist merchandise revenue.
Curexo (KOSDAQ 060280) stock outlook 2026: a deep qualitative look at its CUVIS-joint knee and hip surgical robot, CUVIS-spine, the Morning Walk rehabilitation robot, the THINK Surgical partnership, and how a small-cap challenger stacks up against Stryker Mako, Zimmer Biomet ROSA and J&J VELYS.
Protec (KOSDAQ: 053610) stock outlook 2026, covering its underfill and dam-and-fill dispensers, micro solder ball attach and bumping equipment, exposure to HBM and 2.5D/3D packaging demand, Samsung customer concentration risk, and how it stacks up against Hanmi Semiconductor, ASMPT and BESI.
Heung-A Shipping (003280) 2026 stock outlook: how the former Korean container line rebuilt itself as an intra-Asia chemical and petroleum-products tanker operator under Sinokor, why it trades as a Middle East geopolitics theme stock, its balance-sheet turnaround, and how it stacks up against Korea Line, KSS Line, and Pan Ocean.
Hyundai Bioland (KOSDAQ 052260) stock outlook 2026: a qualitative deep dive into hyaluronic acid and collagen ingredient localization, its supply role feeding Cosmax and Kolmar ODM lines, the Hyundai Department Store Group ownership angle, and microbiome upside.
S-Energy (KOSDAQ 095910) stock outlook 2026. A qualitative deep dive into its dual solar module manufacturing and power-plant EPC/developer business, its ESS expansion, the structural weakness of not owning cell production, China oversupply pressure on module ASPs, and US IRA/tariff policy exposure.
An AP Systems (265520) stock outlook for 2026 covering its ELA and LLO laser equipment, encapsulation and lamination tools, semiconductor RTP annealing gear, Samsung Display customer concentration, the 8th-gen IT OLED investment cycle, foldable tailwinds, Chinese panel-maker equipment localization risk, peers, and what global investors should track each quarter.
SeAH Steel Holdings (KOSPI 003030) stock outlook for 2026: US OCTG pipe demand and tariff protection, the new offshore wind monopile and jacket business, the holding-company NAV discount, how 003030 differs from operating unit SeAH Steel (306200), and peer comparisons against Husteel, NEXTEEL and Dongkuk Steel.
Sangsangin Co (KOSDAQ: 038540) stock outlook 2026: the FSC-ordered divestiture of Sangsangin Savings Bank and Sangsangin Securities, bidder history including OK Savings Bank and Suhyup Bank, valuation-versus-regulatory-discount math, PF loan delinquency risk, and metrics to track.
Neptune (KOSDAQ: 217270) stock outlook for 2026, covering its status as a Kakao Games-controlled subsidiary, its casual and midcore mobile game lineup, its studio-stake investment model, new-title hit dependency, probability-item regulation risk, and how it stacks up against Devsisters, Joycity, and Wemade.
Shinsung Delta Tech (KOSDAQ 065350) stock outlook 2026: the washing machine balancer and drum business supplying LG Electronics and Whirlpool, cylindrical battery cap and CID parts tied to the Tesla 4680 story, subsidiary Shinsung ST's module and pack structural parts, and the volatility that comes with being a Korean Tesla-theme stock.
Saevit Chem (KOSDAQ: 107640) 2026 outlook: a semiconductor waste-acid recycling cash cow funding a fast-growing black-mass and battery-scrap recycling business that recovers nickel, cobalt and lithium into precursor liquid (MHP), the LG Chem / Korea Zinc joint-venture angle, EU Battery Regulation tailwinds, and metal-price risk for US investors.
Hana Pharm (KOSDAQ 293480) stock outlook 2026: a Korean anesthetic-injectable maker with propofol and remifentanil leadership, narcotics-handling licensing as a real barrier to entry, hospital distribution, dividend cash flow, and drug-pricing and regulatory risk for foreign investors.
Kortek (052330) stock outlook for 2026. A qualitative deep dive into the KOSDAQ maker of casino gaming monitors: its certification moat, exposure to casino capex cycles, diversification into e-boards and medical displays, and the FX and small-cap risks a US investor should weigh.
Sempio Foods (248170) stock outlook for 2026. A deep look at its dominant soy sauce and jang franchise, the Yondu cooking-essence growth story abroad, mature domestic demand, soybean and wheat cost pressure, and its low-multiple asset-value character for a US investor.
eMnet (KOSDAQ 123570) stock outlook 2026, analyzed qualitatively for foreign investors. Covers the search and performance ad-agency commission model, structural dependence on Naver and Google, the listed Japan subsidiary, thin margins, competitive landscape, and US tax and FX considerations.
A qualitative 2026 outlook on Shinhan Alpha REIT (293940), Korea's prime-office listed REIT: Pangyo and Yongsan office assets, semi-annual dividends, how falling rates help, and the vacancy, debt-maturity and rights-offering dilution risks a US investor should weigh.
JW Life Science (234080) 2026 stock outlook. A deep qualitative look at Korea's basic IV fluid oligopoly, the higher-margin TPN parenteral-nutrition engine (Winuf), the Baxter export deal, aging-population demand, capacity CAPEX, drug-pricing risk, and the dividend case.
Kyungbo Pharma (214390) stock outlook 2026 for US investors: a deep look at its cephalosporin antibiotic and contrast-media active pharmaceutical ingredient (API) CDMO business, Chong Kun Dang affiliate demand, drug-price pressure, growth ceiling, and the tax and FX mechanics of holding a Korean-listed stock.
KPX Holdings (092230) 2026 stock outlook. A qualitative deep dive into the KPX Chemical polyol and polyurethane cycle, the persistent Korean holding-company NAV discount, net-cash and dividend durability, value-up catalysts, and the cyclical risks a US investor faces.